Cargando…

Understanding the Mechanisms of Resistance in EGFR-Positive NSCLC: From Tissue to Liquid Biopsy to Guide Treatment Strategy

Liquid biopsy has emerged as an alternative source of nucleic acids for the management of Epidermal Growth Factor Receptor (EGFR)-mutant non-Small Cell Lung Cancer (NSCLC). The use of circulating cell-free DNA (cfDNA) has been recently introduced in clinical practice, resulting in the improvement of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Del Re, Marzia, Crucitta, Stefania, Gianfilippo, Giulia, Passaro, Antonio, Petrini, Iacopo, Restante, Giuliana, Michelucci, Angela, Fogli, Stefano, de Marinis, Filippo, Porta, Camillo, Chella, Antonio, Danesi, Romano
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6720634/ https://www.ncbi.nlm.nih.gov/pubmed/31416192 http://dx.doi.org/10.3390/ijms20163951

Ejemplares similares

erbB in NSCLC as a molecular target: current evidences and future directions
por: Del Re, Marzia, et al.
Publicado: (2020)

Implications of KRAS mutations in acquired resistance to treatment in NSCLC
por: Del Re, Marzia, et al.
Publicado: (2017)

The amount of activating EGFR mutations in circulating cell-free DNA is a marker to monitor osimertinib response
por: Del Re, Marzia, et al.
Publicado: (2018)

Integrating Liquid Biopsy and Radiomics to Monitor Clonal Heterogeneity of EGFR-Positive Non-Small Cell Lung Cancer
por: Cucchiara, Federico, et al.
Publicado: (2020)

The increase in activating EGFR mutation in plasma is an early biomarker to monitor response to osimertinib: a case report
por: Del Re, Marzia, et al.
Publicado: (2019)

Multiple Resistance Mechanisms to Tyrosine Kinase Inhibitors in EGFR Mutated Lung Adenocarcinoma: A Case Report Harboring EGFR Mutations, MET Amplification, and Squamous Cell Transformation
por: Bruno, Rossella, et al.
Publicado: (2021)

Patients with NSCLC may display a low ratio of p.T790M vs. activating EGFR mutations in plasma at disease progression: implications for personalised treatment
por: Del Re, Marzia, et al.
Publicado: (2017)

PD-L1 mRNA expression in plasma-derived exosomes is associated with response to anti-PD-1 antibodies in melanoma and NSCLC
por: Del Re, Marzia, et al.
Publicado: (2018)

A multiparametric approach to improve the prediction of response to immunotherapy in patients with metastatic NSCLC
por: Del Re, Marzia, et al.
Publicado: (2020)

Concise Review: Chronic Myeloid Leukemia: Stem Cell Niche and Response to Pharmacologic Treatment
por: Arrigoni, Elena, et al.
Publicado: (2018)

Adjuvant EGFR TKIs in NSCLC harboring EGFR mutations: looking for a consensus way
por: Attili, Ilaria, et al.
Publicado: (2020)

Contribution of KRAS mutations and c.2369C > T (p.T790M) EGFR to acquired resistance to EGFR-TKIs in EGFR mutant NSCLC: a study on circulating tumor DNA
por: Del Re, Marzia, et al.
Publicado: (2016)

Uncommon EGFR Compound Mutations in Non-Small Cell Lung Cancer (NSCLC): A Systematic Review of Available Evidence
por: Attili, Ilaria, et al.
Publicado: (2022)

Understanding EGFR heterogeneity in lung cancer
por: Passaro, Antonio, et al.
Publicado: (2020)

Nanopore sequencing from liquid biopsy: analysis of copy number variations from cell-free DNA of lung cancer patients
por: Martignano, Filippo, et al.
Publicado: (2021)

The amount of DNA combined with TP53 mutations in liquid biopsy is associated with clinical outcome of renal cancer patients treated with immunotherapy and VEGFR-TKIs
por: Del Re, Marzia, et al.
Publicado: (2022)

Androgen receptor gain in circulating free DNA and splicing variant 7 in exosomes predict clinical outcome in CRPC patients treated with abiraterone and enzalutamide
por: Del Re, M., et al.
Publicado: (2021)

New Generations of Tyrosine Kinase Inhibitors in Treating NSCLC with Oncogene Addiction: Strengths and Limitations
por: Attili, Ilaria, et al.
Publicado: (2023)

Concomitant administration of proton pump inhibitors does not significantly affect clinical outcomes in metastatic breast cancer patients treated with ribociclib
por: Del Re, Marzia, et al.
Publicado: (2022)

Pharmacogenetic Foundations of Therapeutic Efficacy and Adverse Events of Statins
por: Arrigoni, Elena, et al.
Publicado: (2017)

Gemcitabine Plus Nab-Paclitaxel Induces PD-L1 mRNA Expression in Plasma-Derived Microvesicles in Pancreatic Cancer
por: Del Re, Marzia, et al.
Publicado: (2021)

Radiomics and liquid biopsy in oncology: the holons of systems medicine
por: Neri, Emanuele, et al.
Publicado: (2018)

A Real-World Application of Liquid Biopsy in Metastatic Colorectal Cancer: The Poseidon Study
por: Procaccio, Letizia, et al.
Publicado: (2021)

Discovery of novel mutations in the dihydropyrimidine dehydrogenase gene associated with toxicity of fluoropyrimidines and viewpoint on preemptive pharmacogenetic screening in patients
por: Del Re, Marzia, et al.
Publicado: (2015)

Assessment of EGFR Mutations in Circulating Tumor Cell Preparations from NSCLC Patients by Next Generation Sequencing: Toward a Real-Time Liquid Biopsy for Treatment
por: Marchetti, Antonio, et al.
Publicado: (2014)

MET in Non-Small-Cell Lung Cancer (NSCLC): Cross ‘a Long and Winding Road’ Looking for a Target
por: Spitaleri, Gianluca, et al.
Publicado: (2023)

Amivantamab in the Treatment of Metastatic NSCLC: Patient Selection and Special Considerations
por: Petrini, Iacopo, et al.
Publicado: (2022)

Sustained Improvement in the Management of Patients with Non-Small-Cell Lung Cancer (NSCLC) Harboring ALK Translocation: Where Are We Running?
por: Spitaleri, Gianluca, et al.
Publicado: (2023)

Genomic Characterization of Concurrent Alterations in Non-Small Cell Lung Cancer (NSCLC) Harboring Actionable Mutations
por: Passaro, Antonio, et al.
Publicado: (2021)

Aumolertinib in NSCLC with leptomeningeal involvement, harbouring concurrent EGFR exon 19 deletion and TP53 comutation: a case report
por: Qin, Zhiquan, et al.
Publicado: (2023)

Use of liquid biopsy in monitoring therapeutic resistance in EGFR oncogene addicted NSCLC
por: Iacovino, Marialucia, et al.
Publicado: (2020)

CDK4/6 Inhibitors Overcome Endocrine ESR1 Mutation-Related Resistance in Metastatic Breast Cancer Patients
por: Crucitta, Stefania, et al.
Publicado: (2023)

Future Perspectives in Detecting EGFR and ALK Gene Alterations in Liquid Biopsies of Patients with NSCLC
por: Ferreira, Daniela, et al.
Publicado: (2021)

Liquid Biopsy as a Tool Exploring in Real-Time Both Genomic Perturbation and Resistance to EGFR Antagonists in Colorectal Cancer
por: Internò, Valeria, et al.
Publicado: (2020)

Afatinib for the Treatment of Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: An Updated Database of 1023 Cases Brief Report
por: Yang, James Chih-Hsin, et al.
Publicado: (2022)

Can Liquid Biopsy Based on ctDNA/cfDNA Replace Tissue Biopsy for the Precision Treatment of EGFR-Mutated NSCLC?
por: Li, Yi-Ze, et al.
Publicado: (2023)

Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients
por: Del Re, M., et al.
Publicado: (2021)

Reply to comments on: Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients
por: Del Re, M., et al.
Publicado: (2022)

Systemic Therapy for Oligoprogression in Patients with Metastatic NSCLC Harboring Activating EGFR Mutations
por: Rossi, Antonio, et al.
Publicado: (2022)

Unexpected responses to EGFR inhibition in NSCLC
por: Stella, Giulia M., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_pihrs5bnb96dao3i8l648luk9i